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Objective and background. Pulmonary aneurysms and thrombosis constitute a signiﬁcant cause of morbidity and mortality in
Behc ¸et’s disease (BD). Various factors have been studied to explore the pathogenesis of vascular involvement in BD. As endothelin
(ET) is known for its potent vasoconstrictor and proinﬂammatory properties, we supposed that it is involved during the inﬂam-
matory process of BD pulmonary vasculitis. Methods. To investigate the role of ET in BD, ET-1 concentrations were measured
in bronchoalveolar lavage ﬂuid (BALF) of 18 nonsmoking BD patients with pulmonary manifestations and 12 control subjects.
Immunoreactivity of ET-1 was also evaluated in alveolar macrophages (AMs) cytoplasm. Results.E T - 1l e v e l si nB D - B A L Fw e r e
signiﬁcantly higher than those of controls. ET-1 levels were correlated with the number of alveolar macrophages, but not with
BAL-CD4/CD8 ratio. ET-1-immunoreactivity was found mainly in AM of BD-BAL. Conclusions. Increased ET-1 production from
AM is associated with pulmonary BD manifestations.
Copyright © 2007 Kamel Hamzaoui et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Behc ¸et’s disease (BD) is a multisystem inﬂammatory dis-
order characterized by recurrent oral ulcers, genital ulcers,
and ocular inﬂammation, and frequently involves the joints,
skin, gastrointestinal tract, central nervous system (CNS),
and pulmonary manifestations [1–3]. BD is recognized as
a multisystem vasculitis, which can aﬀect all types of blood
vessels [1]. During the course of BD, 25–37% of patients de-
velop vascular complications [1–4].
Recent evidence suggests that ET should be considered
to be an inﬂammatory mediator [5, 6]a n dc a ns t i m u l a t e
macrophages and monocytes to release proinﬂammatory cy-
tokines. Recent data also indicated that endothelial dysfunc-
tion (ED) is a constant feature of BD [7]. Etiology of ED in
BD is probably multifactorial. Activation of both innate and
Th1-type adaptive immune responses with enhanced expres-
sion of proinﬂammatory cytokines, adhesion molecules, free
oxygenradicals[8],andhighhomocysteinelevels[7]ha v eall
been suggested responsible for the activation of endothelial
cells irrespective of overt vascular manifestations. Chambers
et al. [9] observed an increase in FMD (brachial artery ﬂow-
mediated endothelium-dependent dilation) values following
vitamin C administration in 12 patients, suggesting an im-
portant role of oxidative stress in endothelial dysfunction in
BD. Inﬂammatory microenvironment in BD may cause re-
duced bioavailability of nitric oxide through proinﬂamma-
tory cytokines as well as increased oxidized LDL cholesterol
levels [10, 11].
ET has both mitogenic and proliferative actions on ﬁ-
broblasts [12] in vitro and is produced by many types of lung
cells such as endothelial cells [13], epithelial cells [14]a n d
macrophages [6]. Interestingly, a recent study using human
ET-1 transgenic mice has demonstrated that pulmonary ET-
1 overexpression causes lung ﬁbrosis [15]. ET-1 also induces
ﬁbronectin expression in human bronchial epithelium via an
ETA receptor [16], suggesting a contribution of ET-1 as the
intermediate pathogenesis of ﬁbrosis because ﬁbronectin is a
potent chemotactic factor for ﬁbroblasts [16].
On this background, our study was planned to assess the
contribution of bioactive ET to the pulmonary BD manifes-
tations.Forthispurpose,ETconcentrationinBALFfromBD
patients was measured in BAL from active BD patients hav-
ing pulmonary manifestation.
2. MATERIALS AND METHODS
2.1. Patients
We studied 18 active BD patients (12 males and 6 females;
nonsmoking patients; mean age: 49.8 years; range: 28–522 Mediators of Inﬂammation
Table 1: Clinical features of patients with Behc ¸et’s disease (BD)
withpulmonarymanifestations.Overallburdenofthediseaseman-
ifestations in BD patients is described. Patients received colchicine,
steroids/cyclosporine. Five patients with oral ulcer, genital ulcer,
uveitis, and vasculo-symptoms were newly diagnosed. All patients
had pulmonary aneurysms.
Number of patients (%)
Majorcriteria
Oral ulcer 18 (100)
Genital ulcer 18 (100)
Skin lesions (erythema
nodosum, folliculitis) 14 (77.8)
Uveitis 16 (88.9)
Minorcriteria
Arthritis 15 (83.3)
Vascular symptoms 09 (50.0)
Intestinal symptoms 05 (27.8)
years). They were selected on the basis of the criteria deﬁned
by the International Study Group for diagnosis of Behc ¸et’s
disease [17]. Clinical features of the patients with active
stage are given in Table 1, which describe overall burden of
the disease manifestations in BD patients. All active BD pa-
tients have pulmonary manifestations. Active BD patients
were always treated with steroids and colchicine. The con-
trol subjects consisted of 12 nonsmokers (ﬁve men and seven
women; mean age: 46.2 years; range: 32–48 years) undergo-
ing routine investigations for suspected bronchial carcinoma
and whose chest X-ray (CXR), bronchial examination, and
pulmonary functions were normal. None of them had evi-
dence of acute infection or chronic disease (e.g., other au-
toimmune or atopic disorders). Informed consent was ob-
tained from all of the patients and control subjects. The de-
sign of the study was approved by our National Ethics Com-
mittee.
2.2. Bronchoalveolarlavage
Bronchoscopy was performed according to standard guide-
lines, as described previously [18]. Thirty minutes prior
to the procedure patients received 0.5mg of atropine and
12.5mg codeine intramuscularly. Local anaesthesia of the
oropharynx was achieved by Novesine spray (Wander,
Switzerland) until gag reﬂexes subsided. Bronchoscopy was
performed using a Pentax bronchoscope through which
150ml of normal prewarmed saline in aliquots of 20ml were
instilled into a subsegment of the right middle lobe. BAL
ﬂuid was then immediately aspirated by gentle hand suction
into plastic tubes and kept at 4◦Co ni c e .
2.3. ProcessingofBALcells
BAL samples were ﬁltered through a two-layer sterile gauze
into sterile plastic vials (Falcon, Oxnard, CA, USA), cen-
trifuged at 4◦C and 500 grams for 10 minutes. The super-
natant was removed and cells were washed twice in PBS.
The total cell number was counted using a Neubauer hemo-
cytometer (Brand, Wertheim, Germany). Diﬀerential cell
counts were performed after Giemsa staining (Merck, Darm-
stadt, Germany) of cell smears with 1000 cells per slide
counted.
2.4. AnalysisofT-lymphocytesubsetsinBAL
BAL cells were incubated in the presence of saturating con-
centrations of ﬂuorescein-conjugated MoAb against the sur-
face markers CD3, CD4, and CD8 and isotype-matched con-
trol antibodies labelled with FITC, PE, and PE/CY5 (ob-
tained from Dako, Hamburg, Germany) for 20 minutes at
room temperature in the dark. Nonspeciﬁc ﬂuorescence was
detected by incubating mouse IgG of the same isotype, but
with irrelevant antigen speciﬁcity. After two washes with
PBS, the cells were analyzed by ﬂow cytometry (FACScan;
Becton Dickinson, Heidelberg, Germany).
2.5. ExtractionofETandenzymeimmunoassay
Endothelin levels in BALF were assessed as described previ-
ously [19]. Brieﬂy, the BALF sample (5mL, thawed at 4◦C)
was loaded onto Sep-Pak C18 column (Millipore, Milford,
MA, USA) that had been preactivated by methanol, and
washed with 0.1% triﬂuoroacetic acid. Bound ET was eluted
with methanol : water : triﬂuoroacetic acid (90 : 10 : 0.1)
and evaporated by centrifugal freeze dryer. The resulting pel-
let was reconstituted with 500μL of assay buﬀer, and then
the concentration of extracted ET was measured using En-
dothelin Enzyme Immunoassay kit (R&D System Europe,
Ltd., Abingdon Science Park, UK). The detection limit of the
assay was 0.78pg/mL.
2.6. Immunocytochemistry
BAL cells were centrifuged at 300g for 10 minutes. The
slides were air-dried and ﬁxed in acetone. BAL cells were
stained with rabbit mAb to human ET-1 (Biotrend Chem-
icals GmbH; K¨ oln, Germany), using the unlabeled anti-
body method (indirect method). The slides were incubated
for 1 hour at 37◦C with a 1/200 dilution of rabbit mAb
to human ET-1, and incubated with horseradish peroxi-
dase, labeled goat anti-rabbit IgG for a further 1 hour at
37◦C. Peroxidase was visualized by incubating slides in 3,3 -
diaminobenzidine tetrahydrochloride and hydrogen perox-
ide (H2O2)f o r2m i n u t e s .
2.7. Measurementofalbumin
The concentration of albumin in BALF was measured by
ELISA kit (Exocell, Philadelphia, PA, USA). The assay fol-
lowed a conventional ELISA format, using an antibody that
recognizes antigen (albumin) in the test samples.
2.8. Statisticalanalysis
Data are presented as mean ± SE. Comparison of ET-1 levels
in BALF between normal subjects and active BD patients wasKamel Hamzaoui et al. 3
Table 2: BAL ﬂuid results in patients with active Behc ¸et’s disease and control subjects. Data are expressed as mean ± SEM.
Alveolar macrophage data Active BD(†) Controls subjects(†) P value(‡)
Cells per millilitrex 104 18.6 ±2.41 3 .7 ±4.7 .092
% Alveolar macrophages 68.7 ±8.47 2 .4 ±10.7. 0 8
Albumin (mg/L) 29.6 ±3.21 8 .7 ±2.3. 0 7
% ET-1 immunopositive 84.77 ±12.49 1.92 ±0.87 .00006
(†)Data are from 18 BALs performed in 18 active BD patients and 12 BALs performed in 12 control subjects.
(‡)Mann-Whitney U test.
performed using the Student t test for paired samples. Cor-
relations were tested by calculation of Pearson’s correlation
coeﬃcient (r). Calculations were performed using the SPSS
(10.0). P values of <.05 were considered statistically signiﬁ-
cant.
3. RESULTS
3.1. BALdifferentialcellcountandCD4/CD8ratio
BALF recovery volumes were not diﬀerent between active
BD and healthy controls (52.7 ± 9.6% versus 53.4 ± 10.2%;
P = .38). The BAL cell count tended to be higher in active
BD than healthy controls, but did not reach statistical signif-
icance (Table 2). The percentage of lymphocytes was higher
in active BD-BAL than in control subjects [(28.7 ± 10.2%)
versus (16.3 ± 8.5%); P = .0002]. The percentage of 12
macrophages was not signiﬁcantly diﬀerent between active
BDandhealthycontrols[(68.7±8.4%)versus(72.4±10.7%);
P = .08]. No diﬀerences were observed in the percentages of
neutrophils and eosinophils.
The percentage of the CD4+ lymphocytes in BAL of pa-
tientswithactiveBD(68.7%±12.3%)washigherthanthatof
normal controls (52.7% ± 18.5%; P = .037). The CD4/CD8
ratio,inpatientswithactiveBD(2.26±0.8),wassigniﬁcantly
increased when compared to healthy controls (1.16 ± 0.3;
P = .041).
3.2. ET-1levelsinBALF
E n d o t h e l i n - 1l e v e l si nB A L Ff r o ma c t i v eB Dw e r es i g n i ﬁ -
cantly higher in active BD than those from healthy controls
(22.78 versus 7.23ng/mg albumin, P<. 004) (Figure 1).
3.3. CorrelationbetweenET-1concentration
andnumberofalveolarmacrophages
(AMs)inBALF
There was a positive correlation (r = .56; P = .014) be-
tween the number of macrophages and ET-1 levels in BALF
(Figure 2). No correlation (r = .08; P = .734) was found
between ET-1 levels and CD4/CD8 ratio (Figure 3).
3.4. ImmunocytochemistryofET-1
The cytoplasm of BALF cells from patients with active
BD was strongly stained with anti-ET-1, compared to healthy
HC Active BD
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Figure 1: Endothelin-1 concentration in BAL ﬂuid from patients
with active Behc ¸et’s disease (BD) and from healthy controls (HC).
ET-1 levels were measured by enzyme immunoassay and were cor-
rectedbyanalbuminconcentrationinrecoveredlavageﬂuid.Values
wereexpressedasmedianandthe25th–75thpercentile. P valuesare
also indicated (Student t test) (P = .004; t =− 3.620; ddl: 11).
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Figure 2:Correlationbetweenendothelin-1concentrationsandthe
number of alveolar macrophages in BAL ﬂuid from 18 active BD
patients with pulmonary manifestations. (P = .014; r = .56).
controls. The most stained cells in active BD were macro-
phages (Figure 4). The percentage of AMs immunopositive
forET-1wasassessedinﬁveﬁeldsandallofthemacrophages
were immunopositive for ET-1 in active BD BAL (84.77 ±
12.49%), whereas <2% were positively stained in the healthy
controls (Table 2). When macrophages were incubated for
24 hours without stimulation, culture media in active BD
contained higher levels of ET-1 than for healthy controls.4 Mediators of Inﬂammation
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Figure 3: Correlation between endothelin-1 concentrations and
CD4/CD8ratioofalveolarmacrophagesinBALﬂuidfrom18active
BD patients with pulmonary manifestations. (P = .734; r = .08).
(a)
(b)
Figure 4: Immunocytochemical detection of endothelin-1 in BAL
cells from control subjects (a), and from patients with active BD (b)
using rabbit mAb to human endothelin-1. Cytoplasm of BALF cells
from patients with active BD was strongly stained. The immunos-
taining also demonstrated that most of the immunopositive cells in
the BD BALF were macrophages.
4. DISCUSSION
Pulmonary manifestation in BD is one of the leading causes
of death. Mean survival after the onset of hemoptysis was re-
ported to be about 10 months [20, 21]. Recent reports of el-
evated serum concentrations of von Willebrand factor, plas-
minogenactivatorinhibitor-1,andthrombomodulinsuggest
that impaired vascular endothelial function contributes to
vascular pathology in BD [22]. Endothelium-independent
vasodilatation (EIVD) was found to be low in patients with
BD [7].
The source of ET-1 in the lung has been controversial.
In the normal lung, ET-1 is known to be produced by sev-
eral lung cells such as endothelial cells, epithelial cells, and
AM [5]. Increased expression of immunoreactive ET-1 and
ET-1mRNAinpathologicalconditionsincludingpulmonary
manifestations has been demonstrated in AM and proliferat-
ing alveolar epithelial cells [5, 23].
In this study, a signiﬁcant correlation was observed be-
tween ET-1 concentrations and the number of AM. An in-
creased presence of immunoreactive ET-1 in cytoplasm of
AM from BD patients but not healthy controls was revealed
by immunocytochemical assay. These data suggest that ET-1
could play an important role in inﬂammatory lung manifes-
tations in these patients.
A variety of mediators, which could be involved in the
intermediate pathogenesis of lung inﬂammation in BD pa-
tients, has been studied. Proinﬂammatory cytokines such
as TNF-α,I F N - γ, IL-1, IL-6, IL-8, and IL-18 are known
to amplify the inﬂammatory response in BD [18, 24–
26]. Macrophage inhibitory protein-1α (MIP-1α), a C−C
chemokine, which stimulates the activation and migration
of leukocytes, was found elevated in patients with BD, and
correlates with IL-8, Rantes, and MCP-1 levels [27]. The ex-
pression of ET-1 mRNA was increased after incubation with
α-(IL-8 and MGSA/Groα)a n dβ-chemokines (MCP-1, MIP-
1α,M I P - 1 β, and RANTES), and a mixture of 3 proinﬂam-
matory cytokines TNF-α,I L - 1 β,a n dI F N - γ was able to in-
crease the mRNA expression of ET-1 [28]. These data pro-
vide several ﬁndings, the most signiﬁcant of which is a stim-
ulatory role for chemokines on the vascular endothelium.
Our data support a local production of ET-1 within the pul-
monary alveoli. In our study, most of the AMs expressed in-
tracytoplasmicET-1.Thisﬁndingmaybelinkedwiththepo-
larization of T-lymphocytes toward the Th1-type in BD as
Th1cytokinespromoteaccelerationofmacrophagefunction.
Furthermore BAL ﬂuid cells from patients with BD show
increased mRNA expression of IFN-γ and IL-18 compared
with normal controls [18, 29]. In the same way, TNF-α in-
creases the expression of ET-1 in bronchial epithelial cells,
and TNF-α release is itself increased by ET-1 [30]. As a mat-
ter of fact, high TNF-α levels have been observed in BD sera,
positively correlated with IL-18 production [31, 32].
The interaction between ET and various cytokines may
regulate/exacerbate the pathological events in pulmonary
manifestations in BD. ET-1 has been launched as an impor-
tant mediator in bronchi [33]. In animal studies, the increase
in ET-1 mRNA level in lung tissue preceded the increase in
mRNAlevelsofTNF-α,IL -1β,andIL-8.Treatmentofthean-
imals with the ET receptor antagonist bosentan resulted in a
substantial decrease in the concentrations of TNF-α,I L - 1 β,
interferon-γ, and ET-1 in BAL ﬂuid [33]. In BD, the inter-
play between ET-1 and proinﬂammatory mediators must be
elucidated.
Vascular endothelial dysfunction is a central event in the
pathogenesis of a variety of human diseases, including adult
respiratory distress syndrome, atherosclerosis, and diﬀuseKamel Hamzaoui et al. 5
systemic inﬂammatory disorders [34]. Endothelial injury
seems to induce a dysfunction in nitric oxide (eNOS; iNOS)
activity, resulting in a proinﬂammatory environment in as-
sociation with tissue damage [34]. Recently, it has also been
reported that reduced plasma nitric oxide (NO) levels in BD
patients are implicated in the development of the endothe-
lial abnormalities and thrombotic complications occurring
in these patients [35]. An impairment of endothelium-
dependent, ﬂow-mediated dilatation has been described in
BD suggesting a decreased endothelial NO activity, which
may contribute to vascular lesions in BD. However, there
have been conﬂicting reports about serum NO concentra-
tions in patients with BD [36]. Recently, endothelial nitric
oxide synthase gene Glu298Asp polymorphism was signiﬁ-
cantly associated with BD in a randomly selected group of
Turkish patients [37]. The authors discussed the fact that
with respect to the impaired NO production, the signiﬁcant
association of Glu298Asp polymorphism with BD may have
a clinical implication as this polymorphism generates pro-
tein products with diﬀering susceptibility to cleavage. They
discussed the fact that this might have contributed to abnor-
mally low NO generation. The combination of the paracrine
eﬀects of ET-1 along with release of NO is likely to have a
relevant physiological role in the regulation of blood ﬂow, as
ET-1 and NO have opposite eﬀects. ET-1 induces vasocon-
striction and thrombosis contributing to ocular pathological
manifestationsandpromotingretinalcapillarynonperfusion
and ischaemia [38]. Increased levels of VEGF and MCP-1 de-
tected in BD thrombosis suggest the possible role of those
angiogenic cytokines together with ET-1 in the pathogenesis
ofthedisease.Moreover,ET-1hasmitogenicproperties,with
animal studies indicating a role in the proliferation of cul-
tured airway smooth muscle cells and airway epithelial cells.
The presence of endothelin-1 in increased concentration in
BD patients’ lungs suggests that further investigation of its
role in pulmonary vessel remodeling is justiﬁed and poten-
tial interactions of endothelin-1 with other growth factors in
BD remain to be clariﬁed.
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